Merck Sharp + Dohme Corp.

Bhagwant Rege

Justin Moser

Craig A McKelvey

Laman L Alani

Soumojeet Ghosh

Majid Mahjour

Sutthilug Sotthivirat

Maria T Cruanes

Sarah Geers

Dina Zhang

Haihong Fan

Agam R Sheth

Craig A Mckelvey

The instant invention relates to pharmaceutical compositions containing cathespin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions.

Formulations for cathepsin K inhibitors

A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)&#x3e;10. 

Self-emulsifying formulations of CETP inhibitors

Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.

CB-1 receptor modulator formulations

Growing community of inventors

Collegeville, PA, United States of America

Bhagwant Rege